The Law Firm of Weiss & Lurie Investigates the Acquisition of Martek Biosciences Corporation by Royal DSM N.V.
December 22 2010 - 10:18AM
Business Wire
Weiss & Lurie, a national class action and shareholder
rights law firm with offices in New York City and Los Angeles, is
investigating possible breaches of fiduciary duty and other
violations of law by members of the Board of Directors of Martek
Biosciences Corporation (“Martek” or the “Company”) (NASDAQ: MATK)
arising from the proposed acquisition of Martek by Royal DSM N.V.
(“DSM”) (NYSE Euronext: DSM KON) for $31.50 per share. The
transaction is valued at approximately $1.09 billion and is
expected to close in the first half of 2011.
Weiss & Lurie is investigating whether Martek’s Board acted
in shareholders’ best interests in approving the transaction,
whether the Board adequately shopped the Company so as to maximize
shareholder value, and if the Company has made proper disclosure to
its shareholders.
If you own Martek shares and would like more information about
your rights as a shareholder or additional information concerning
our investigation, please contact Michael A. Rogovin either by
email at infony@weisslurie.com or by telephone at (888)
593-4771.
Weiss & Lurie has litigated hundreds of stockholder class
and derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for defrauded
institutions and individuals and obtained important corporate
governance in these cases. If you have information or would like
legal advice concerning possible corporate wrongdoing (such as
insider trading, waste of corporate assets, accounting fraud, or
issuing materially misleading press releases or SEC filings),
consumer fraud (such as false advertising, defective products, or
other deceptive business practices), or anti-trust violations,
please email us at infony@weisslurie.com or fill out the form on
our website, http://www.weisslurie.com/contact/report_fraud/.
Attorney Advertising. Past results do not guarantee a similar
outcome.
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Martek Biosciences Corp. (MM) (NASDAQ): 0 recent articles
More Weiss & Lurie News Articles